1 -I, agenda HEALTH.

Cancer Mortality, by State--1994 ....................................................... 2 4 4 5 6 7 8 SELECTED CANCERS............................................................................ 9 Lung Cancer.............................................................. 9 Colon and Rectum Cancer...................................................................... 9 Breast Cancer..............................................................................................10 Prostate Cancer.......................................................................................... 10 Leading Sites of Cancer Incidence and Death--1994 Estimates.................................................................................................. 11 How to Estimate Cancer Statistics Locally.......................................... 12 Pancreas Cancer......................................................................................... 12 Uterus (Cervix) Cancer............................................................................. 12 Percentage of Population (Probability) Developing Invasive Cancers at Certain Ages.........................................................13 Uterus (Endometrial) Cancer................................................................... 13 Cancer in Children.....................................................................................13 Leukemia..................................................................................................... 14 Lymphoma...................................................................................................14 Skin Cancer............................................................. 15 Tables are indicated in bold print Ovary Cancer............................................................................................ 15 Five-Year Relative Survival Rates by Stage at Diagnosis................. 16 Bladder Cancer...........................................................................................16 Oral Cancer..............................................................................................

The metabolic pathways of coumarin in the human body lead to the intermediate 7-OH-coumarin and consequent glucuronidation in the intestine and liver.

In 30 years, B.A.S.S. has become one of the nation's leading publishers and multi-media companies in the outdoor field.

On the other hand, a convincing demonstration that computer simulation modeling: applied to existing data for CP can lead to useful insights and quantitative results about dose-response relations in humans would raise confidence that application of the approach to benzene might also yield valuable results.

However the administration of plasticisers,fats or hypolipidaemic drugs to non-rodent species such as the marmoset (a primate considered to be metabolieally closer to humans) does not lead to peroxisome proliferation and liver damage.

Incidence of subcutaneous sarcomas in rats, following local injection of some inorganic pigments Treatment No. of animals Chromium yellow (lead chromate) Chromium oranae dead chromate) Molybdenum orange Head chromate and molybdenum chromate) Cadmium yellow (cadmium sulphide) Iron red 1 iron oxide) Iron yellow (iron oxide) Controls 40 40 40 40 40 40 60 No. of tumours 26 26 36 13 1 0 0 PPG 190 Occupational carcinogenesis meetings and commissions, but of course, in the meantime the existing occupational exposure continues Also, imperfect testing, for example the subcutaneous injection in the rar of compounds, to which man is exposed mainly by the respiratory route, may give some idea of their potential oncogenic risk.

\ _A-Division of The Society of The Plastics Industry, Inc.

A Division of The Sociei y of The Plastics Industry, Inc.

CALIFORNIA LIST CONSTITUENTS AND THEIR PROHIBITION LEVELS CONSTITUENT CONCENTRATION (MG/L) Cyanides Arsenic Cadmium Chromium VI Lead Mercury Nickel Selenium Thallium Liauids with pH s 2.0 Hazardous Waste Liquids with PCBs Wastes containing HOCs* ' Halogenated Organic Carbon (See 40 CFR Appendix III). 1.000 500 100 500 500 20 134 100 130 -- 50 ppm 1.000 mg/kg I------- 1 --II indicated by "X." any or ail of the above specified waste codes are referenced to certification statement Section VI.

Lead Prevalence Study (1993-4) $5,000 Co-Principal Investigator Occupational Upper Extremity Disorders Clinic University of Massachusetts Medical Center (1993-4) $57,000 ~ Principal Investigator.

EPA Cancer R&S147685 .4- Assessment Group found that alternative plausible modeling assumptions would lead to risk estimates that were 15-fold to 10,000-fold lower than the standard LMS procedure.

TO: Rick Smith TGG: jetj ^JT^iC:^AJO: RF XF: v\ ^...

However the administration of plasticisers,fats or hypolipidaemic drugs to non-rodent species such as the marmoset (a primate considered to be metabolically closer to humans) does not lead to peroxisome proliferation and liver damage.

Lead Prevalence Study (1993-4) $5,000 Co-Principal Investigator Occupational Upper Extremity Disorders Clinic University of Massachusetts Medical Center (1993-4) $57,000 Principal Investigator.